July 1, 2025 7:34am

Econs are actionable with another bang having resurrected!

Not a lot of action in the aftermarket followed by the pre-open

News: Mesoblast (MESO +$0.81 or +7.44% to $11.70 pre-open) announced alignment with the FDA on items required for filing a Biologics License Application (BLA) for Revascor® (rexlemestrocel-L) in the treatment of patients with ischemic heart failure with reduced ejection fraction (HFrEF) and inflammation. MESO intends to file by the end of the year for accelerated approval in patients with end-stage ischemic HFrEF implanted with an LVAD.

The last session of June is today and then markets will close at 1 p.m. on Thursday and remain shut on Friday for the 4th of July.

Never leave an investor uninformed …

I say what others won’t, so you can do what others can’t!

Remember that overnight and pre-open actions’ futures and markets doesn’t necessarily translate into actual trading in today’s market session.

“I also hate to be so negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!”

My interpretation of the morning’s numbers is written to be informative; it’s built on what happened to make “it” happen today!

 

Monday’s night’s … RegMed Investors (RMi) Closing Bell: the sword hung by a single horsehair, implying an ever-present peril facing share pricing … https://www.regmedinvestors.com/articles/13980

RegMed Investors (RMi) Research Note: Harvard Apparatus GT (OTCQB): PONZI Scheme at its best or was convicted Bernie Madoff also resurrected … https://www.regmedinvestors.com/articles/13812

 

Tuesday: The pre-open Dow futures are DOWN -0.08% or (-37 points), the S&P futures are DOWN -0.20% or (-12 points) and the Nasdaq futures are DOWN -0.25% or (-58 points)

  • U.S. equity futures are falling early Tuesday, 7/1 after another record close,
  • European markets were falling after a positive open,
  • Asia-Pacific markets trade mixed

 

Henry’omics: We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies

  • Monday: The Dow closed UP +275.50 points or +0.63%, the S&P closed UP +31.88 points or +0.52% while the Nasdaq closed UP +96.28 points or +0.48%
  • Friday: The Dow closed UP +432.43 points or +1%, the S&P closed UP +32.05 points or +0.52% while the Nasdaq closed UP +105.54 points or +0.52%

Economic Data Docket: JOLTS Job Openings, May (7.26 million expected, 7.39 previously); ISM manufacturing, June (48.8 expected, 48.5 prior); Construction spending month-over-month, May (+0.1% expected, -0.4% prior); Dallas Fed services activity (-10.1 prior); S&P Global US manufacturing PMI, June (52 expected, 52 prior)

 

Q3 – July – 1st session

Q2  

  • June – 1 market holiday, 1 neutral, 8 negative, and 11 positive closes
  • May – 1 market holiday, 10 negative and 11 positive closes
  • April – 10 negative and 11 positive closes

 

Companies in my headlights – It’s your decision; I provide ideas and context

I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths.  A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

  • Yet again, I am passing on forecasting the daily indications due to the effects of econs and a shorter week to expectation … it is still a mix of ups, downs and just uncertainty

Although:

  • Moderna (MRNA) closed up +$0.43 after Friday’s -$0.38, Thursday’s +$0.68, Wednesday’s +$0.06, last Tuesday’s +$1.13 and the previous Monday’s -$0.26 with a negative -$0.09 or -0.33% pre-open
  • Mesoblast (MESO) closed up down -$0.03 after Friday’s +$0.17 after Thursday’s +$0.20 and Wednesday’s +$0.10 with a positive +$0.81 or +7.44% on FDA news

 

The BOTTOM LINE: July is here and summer doldrums and vacations and selling before the earnings cycle to pay for the hot dogs.

  • More pressure to come into the economy [and that will lead to] income and share price erosion and a consumer spending slowdown. That is really the picture that we should expect in the 2H/25

 

UGLY:

Sage Therapeutics (SAGE) is laying-off most of its employees - 330 jobs after announcing its planned acquisition by Supernus Pharmaceuticals (SUPN) earlier this month

 

To characterize July, we need to review the last week of June ’25: to understand the “flow” of markets, the cell and gene therapy sector and economic karma…

  • 6/30 - Monday closed positive with 20 positive, 11 negative and 4 flats

Last week:

  • 6/27 – Friday closed negative with 10 positive, 21 negative and 4 flats
  • 6/26 - Thursday closed negative with 14 positive, 18 negative and 3 flats
  • 6/25 - Wednesday closed negative with 14 positive, 17 negative and 4 flats
  • 6/24 - Tuesday closed positive with 30 positive, 3 negative and 2 flats
  • 6/23 - Monday closed negative with 15 positive, 16 negative and 4 flats

 

Reiterating, “There are always some big ifs, especially given some of the headlines that could emanate after a past few months of news flatulence.

  • Some believe in a “June Swoon;” however, now July will be no better or worse than June. Although, I consider the so-called summer rally ... peripatetic or wandering.”

As always, brace ourself for more volatility, economics and their down trending affect?

Welcome to my world of defining the “grey’ in our universe!

  • The sector is what it is, until it isn’t and even then, it doesn’t seem to be… as NOT much changes as the sector’s share pricing rides the waves of volatility, algorithms, electronic trading and short covering.
  • I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities.

I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed.